Shattuck Labs, Inc.
Shattuck Labs is a U.S.-based clinical-stage biotechnology company focused on discovering and developing antibody-based therapies for immune-mediated diseases. The company’s pipeline has centered on programs such as SL-325 and earlier candidates, with research, development, and clinical operations conducted from its U.S. offices in Austin, Texas and Durham, North Carolina.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaAntibody-based therapeutic programs being advanced through preclinical and clinical development.
Revenue from research, licensing, and collaboration agreements with third parties.
Internal research activities that generate new therapeutic candidates and platform insights.
Asiakkaat
Shattuck Labs does not sell approved commercial products; its economic counterparties are pharmaceutical and biotechnology partners, research collaborators, and potential future licensing or development partners. Its programs are aimed at patients with immune-mediated diseases, while current revenue is tied to collaboration and license agreements rather than product sales.
Partners that enter research, option, or license agreements around Shattuck’s antibody programs and platform assets.
Organizations that may support or co-develop later-stage trials, manufacturing, or commercialization.
The eventual end users of approved therapies targeting inflammatory and immune-mediated conditions.
Strategia
The company’s strategy is to advance antibody programs for immune-mediated diseases, with emphasis on clinical development of SL-325 and related pipeline assets. It also seeks to balance internal scientific capability with outsourced clinical research and manufacturing, while preserving flexibility to fund development through collaborations and capital raises.
Clinical progress is the main value driver for a company without commercial products.
More in-house expertise can improve execution in research, process development, and clinical operations.
Collaborations can provide non-dilutive funding and external validation of the platform.
Maantiede
Shattuck Labs is headquartered and operates in the United States, with corporate offices in Austin, Texas and Durham, North Carolina. Its research and development footprint is U.S.-based, while clinical and manufacturing activities are outsourced to third-party organizations that may operate in multiple jurisdictions.
Riskit
Shattuck Labs faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory approval risk, and dependence on external funding before any commercial product exists. Its business also depends on third-party CROs and contract manufacturers, making execution, supply, and quality control important sources of risk.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Product candidates may not show sufficient safety or efficacy in trials.
Kohdistuu: SL-325 and other immune-mediated disease programs
- Capital dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The company has no commercial product revenue and must fund long development cycles.
Kohdistuu: Operating runway and trial funding
- Third-party manufacturing and trial executionVaikutus: KorkeaTodennäköisyys: Korkea
CROs and contract manufacturers control key parts of development and supply.
Kohdistuu - Intellectual property protectionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Patent coverage is needed to protect candidate molecules, methods, and formulations.
Kohdistuu: Platform technology and lead programs
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger companies and other clinical-stage peers are pursuing similar immune targets.
Kohdistuu: TL1A/DR3-axis and broader immune-mediated disease space
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized as performance obligations are satisfied, so timing can be uneven across periods.
Vaikutus: Affects reported quarterly and annual revenue
The company relies on third parties for trials and manufacturing, requiring estimates for unpaid services.
Vaikutus: Affects operating expenses and liabilities
Equity awards are a meaningful part of employee compensation and require valuation assumptions.
Vaikutus: Affects operating expense and dilution analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Corbus Pharmaceuticals Holdings, Inc.
CRBP · Pharmaceutical Preparations
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Päivitetty: 24.9.2026